Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis

Pediatric Rheumatology

Volumn 11, Issue 1, 2013, Pages

  Gilliam, Brooke E ^a   Chauhan, Anil K ^a   Moore, Terry L ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti cyclic citrullinated peptide antibodies; Juvenile idiopathic arthritis; Type II collagen; Vimentin

Indexed keywords

ALPHA ENOLASE; ALPHA ENOLASE ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CITRULLINATED TYPE II COLLAGEN ANTIBODY; CITRULLINATED VIMENTIN ANTIBODY; COLLAGEN ANTIBODY; COLLAGEN TYPE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FIBRINOGEN; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; ENTHESITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOREACTIVITY; JOINT INJURY; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84883075773     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-11-31     Document Type: Article

References (26)

1. Aletha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2010, 2010(69):1580-1588.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
3. Klareskog L, Rönnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-675. 10.1146/annurev.immunol.26.021607.090244, 18173373.
4. Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, Emad Y. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine 2013, 80:38-43. 10.1016/j.jbspin.2012.03.008, 22575064.
5. Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immuno Invest 2008, 37:849-857.
6. Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol 2008, 26:492-497.
7. Avčin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi MO, Meroni PL. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611. 10.1136/ard.61.7.608, 1754144, 12079901.
8. Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Göksel A, Saribas S, Arisoy N, Kocazeybek B. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1687-1689. 10.1136/ard.2003.019331, 1754844, 15547097.
9. Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL. Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2011, 9:8. 10.1186/1546-0096-9-8, 3071779, 21439056.
10. Syed RH, Gilliam BE, Moore TL. Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:1049-1051.
11. Yoshida M, Tsuji M, Kurosaka D, Kurosaka D, Yasuda J, Ito Y, Nishizawa T, Yamada A. Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. Mod Rheumatol 2006, 16:276-281. 10.1007/s10165-006-0498-y, 2780673, 17039307.
12. Uysal H, Bockerman R, Nandakumar KS, Sehnert B, Bajtner E, Engström T, Serre G, Burkhardt H, Thunnissen MM, Holmdahl R. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009, 206:449-462. 10.1084/jem.20081862, 2646582, 19204106.
13. Van Steendam K, Tilleman K, Deforce D. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology 2011, 50:830-837. 10.1093/rheumatology/keq419, 3077912, 21278075.
14. Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 2009, 47:1525-1530.
15. Morbach H, Dannecker H, Karkau T, Girschick HJ. Prevalence of antibodies against mutated citrullinated vimentin and cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2010, 28:800.
16. Burkhardt H, Sehnert B, Bockerman R, Engström T, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005, 35:1643-1652. 10.1002/eji.200526000, 15832289.
17. Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, Elias B, Ménard HA, Newkirk M, Fritzler MJ, Toes RE, Huizinga TW, El-Gabalawy HS. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008, 58:3000-3008. 10.1002/art.23763, 18821680.
18. Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engström A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmström V. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010, 62:44-52. 10.1002/art.25036, 20039432.
19. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204. 10.1136/ard.2004.029389, 1755615, 15640269.
20. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor PC, Venables PJ. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1421-R1429. 10.1186/ar1845, 1297593, 16277695.
21. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, Mikuls TR, Venables PJ. Antibodies to citrullinated α-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008, 58:3009-3019. 10.1002/art.23936, 18821669.
22. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Rantapää-Dahlqvist S. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008, 35:1002-1008.
23. van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga WJ, Toes RE, van der Helm-van Mil AH. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009, 60:2232-2241. 10.1002/art.24716, 19644872.
24. Lindsley CB, Janecek LL, Horton WA, Lindsley HB. IgG anticollagen antibodies in sera of patients with childhood rheumatic diseases [abstract]. Arthritis Rheum 1980, 23:S56.
25. Myers LK, Higgins GC, Finkel TH, Reed AM, Thompson JW, Walton RC, Hendrickson J, Kerr NC, Pandya-Lipman RK, Shlopov BV, Stastny P, Postlethwaite AE, Kang AH. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum 2001, 44:1775-1781. 10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V, 11508428.
26. Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:623-628. 10.1002/art.1780390413, 8630112.